Literature DB >> 3959025

A common structural model for central nervous system drugs and their receptors.

E J Lloyd, P R Andrews.   

Abstract

On the basis of the hypothesis that there is a common structural basis for central nervous system (CNS) drug action consisting primarily of an aromatic group and a nitrogen atom, a four-point model for a common pharmacophore is defined with use of five semirigid CNS-active drug molecules: morphine, strychnine, LSD, apomorphine, and mianserin. Two of the points of the model represent possible hydrophobic interactions between the aromatic group and the receptor, while the other two represent hydrogen bonding between the nitrogen atom and the receptor. The model is then extended by the inclusion of nine additional CNS-active drug molecules: phenobarbitone, clonidine, diazepam, bicuculline, diphenylhydantoin, amphetamine, imipramine, chlorpromazine, and procyclidine, each being chosen as a key representative of a different CNS-active drug class or neurotransmitter system. Consideration of all phenyl group and nitrogen atom combinations, as well as all feasible conformations, shows that all nine molecules closely fit the common model in low-energy conformations. It is proposed that the model may eventually be used to design CNS-active drugs by mapping the relative locations of secondary binding sites. It can also be used to predict whether a given structure is likely to show CNS activity: a search over 1000 entries in the Merck Index shows a high probability of CNS activity in compounds fitting the common structural model.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3959025     DOI: 10.1021/jm00154a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Computer based screening of compound databases: 1. Preselection of benzamidine-based thrombin inhibitors.

Authors:  T Fox; E E Haaksma
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

2.  Strategies for the determination of pharmacophoric 3D database queries.

Authors:  J H Van Drie
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

3.  Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.

Authors:  P A Pierce; J Y Kim; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

4.  Computational models to predict blood-brain barrier permeation and CNS activity.

Authors:  Govindan Subramanian; Douglas B Kitchen
Journal:  J Comput Aided Mol Des       Date:  2003-10       Impact factor: 3.686

5.  Geometries of functional group interactions in enzyme-ligand complexes: guides for receptor modelling.

Authors:  M Tintelnot; P Andrews
Journal:  J Comput Aided Mol Des       Date:  1989-03       Impact factor: 3.686

6.  Towards an identification of the pyrethroid pharmacophore. A molecular modelling study of some pyrethroid esters.

Authors:  J R Byberg; F S Jørgensen; P D Klemmensen
Journal:  J Comput Aided Mol Des       Date:  1987-10       Impact factor: 3.686

7.  Conformation-activity relationships of opiate analgesics.

Authors:  J Martin; P Andrews
Journal:  J Comput Aided Mol Des       Date:  1987-04       Impact factor: 3.686

8.  Searching for pharmacophores in large coordinate data bases and its use in drug design.

Authors:  R P Sheridan; A Rusinko; R Nilakantan; R Venkataraghavan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Identification of 5-hydroxytryptamine1A receptor agents using a composite pharmacophore analysis and chemical database screening.

Authors:  A J Sleight; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

10.  In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile.

Authors:  Chandran Remya; Kalarickal Vijayan Dileep; Ignatius Tintu; Elessery Jayadevi Variyar; Chittalakkottu Sadasivan
Journal:  J Mol Model       Date:  2012-11-16       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.